文献速递神经肌肉病

解决重症肌无力临床试验中结局测量工具的变异性问题

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials.
PubMed 文献 · Neurology · 2023-04-19

重症肌无力(MG)临床试验增多,但结局测量实施缺乏标准化导致研究团队困惑和数据变异。MGNet组织专家总结关键结局测量工具并召开研讨会,形成共识建议,修改了部分工具的指导说明和特定条目,如MG复合量表、QMG-R修订版等,并公开征求意见。建议制作培训材料和修订版源文件免费提供,QMG-R修订版变化需进一步研究验证。

要点

  • MGNet共识建议修改MG-ADL、MG-QoL-15r和MG-Impairment Index的指导说明细节。
  • MG复合量表推荐规范受试者体位及非MG原因无法完成条目的评分方法。
  • QMG评分需最大关注,修改指导说明和条目表现形成QMG-R修订版,需进一步验证。

核心结论

  • MGNet专家共识对MG临床试验中关键结局测量工具提出修改建议,以减少实施变异性,QMG-R修订版的变化需进一步研究验证。

研究设计与样本

  • MGNet(NIH支持的MG罕见病临床研究网络)组织专家组总结MG临床试验关键结局测量工具,召开研讨会形成共识建议,修改建议经公开征求意见后定稿。

主要发现

  • MG-ADL、MG-QoL-15r和MG-Impairment Index的修改仅限于增加指导说明细节。
  • MG复合量表提供了受试者正确体位及非MG原因无法完成条目的评分建议。
  • QMG评分需最多关注,修改指导说明和特定条目表现,形成QMG-Revised。
  • 干预后状态被认为在临床试验中作用有限,但最小表现状态概念除外。

关键数值与推荐

  • 下一步将制作培训材料和修订版源文件,免费提供给研究团队并发布在MGNet网站。
  • 需进一步研究验证QMG-Revised的修改。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究验证QMG-Revised的修改。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An increasing number of clinical trials are enrolling patients with myasthenia gravis (MG). A lack of standardization in the performance of outcome measures leads to confusion among site research teams and is a source of variability in clinical trial data. MGNet, the NIH-supported Rare Disease Clinical Research Network for MG, views standardization of MG outcome measures as a critical need. To address this issue, a group of experts summarized key outcome measures used in MG clinical trials and a symposium was convened to address issues contributing to outcome measure variability. Consensus recommendations resulted in changes to outcome measure instructions and, in some cases, modifications to specific instruments. Recommended changes were posted for public commentary before finalization. Changes to the MG-Activities of Daily Living, MG-Quality of Life-15r, and MG-Impairment Index were limited to adding details to the administration instructions. Recommendations for proper positioning of participants and how to score items that could not be performed because of non-MG reasons were provided for the MG Composite. The Quantitative MG (QMG) score required the most attention, and changes were made both to the instructions and the performance of certain items resulting in the QMG-Revised. The Postintervention Status was believed to have a limited role in clinical trials, except for the concept of minimal manifestation status. As a next step, training materials and revised source documents, which will be freely available to study teams, will be created and posted on the MGNet website. Further studies are needed to validate changes made to the QMG-Revised.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Guptill JT, Benatar M, Granit V, et al. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology. 2023. PMID: 37076302. doi:10.1212/WNL.0000000000207278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。